Targeting treatment of bladder cancer using PTK7 aptamer-gemcitabine conjugate

Targeting treatment of bladder cancer using PTK7 aptamer-gemcitabine conjugate

Abstract Background Gemcitabine (GEM) is one of the first-line chemotherapies for bladder cancer (BC), but the GEMs cannot recognize cancer cells and have a low long-term response rate and high recurrence rate with side effects during the treatment of BC. Targeted transport of GEMs to mediate cytoto...

Full description

Bibliographic Details
Main Authors: Wei Xiang, Yongbo Peng, Hongliang Zeng, Chunping Yu, Qun Zhang, Biao Liu, Jiahao Liu, Xing Hu, Wensu Wei, Minhua Deng, Ning Wang, Xuewen Liu, Jianfei Xie, Weibin Hou, Jin Tang, Zhi Long, Long Wang, Jianye Liu
Format: Article
Language:English
Published: American Association for the Advancement of Science (AAAS) 2022-12-01
Series:Biomaterials Research
Subjects:
Aptamer
PTK7
Bladder cancer
Targeted therapy
PTK7-GEMs
Online Access:https://doi.org/10.1186/s40824-022-00328-9

Internet

https://doi.org/10.1186/s40824-022-00328-9

Similar Items